Abstract
The hedgehog (Hh) pathway is a developmental signaling pathway that is essential to the proper embryonic development of many vertebrate systems. Dysregulation of Hh signaling has been implicated as a causative factor in the development and progression of several forms of human cancer. As such, the development of small molecule inhibitors of Hh signaling as potential anti-cancer chemotherapeutics has been a major area of research interest in both academics and industry over the past ten years. Through these efforts, synthetic small molecules that target multiple components of the Hh pathway have been identified and advanced to preclinical or clinical development. The goal of this review is to provide an update on the current status of several synthetic small molecule Hh pathway inhibitors and explore the potential of several recently disclosed inhibitory scaffolds.
Keywords: Basal cell carcinoma, gli, hedgehog signaling, medulloblastoma, smoothened, synthetic small molecules.
Current Medicinal Chemistry
Title:Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Volume: 22 Issue: 35
Author(s): C.A. Maschinot, J.R. Pace and M.K. Hadden
Affiliation:
Keywords: Basal cell carcinoma, gli, hedgehog signaling, medulloblastoma, smoothened, synthetic small molecules.
Abstract: The hedgehog (Hh) pathway is a developmental signaling pathway that is essential to the proper embryonic development of many vertebrate systems. Dysregulation of Hh signaling has been implicated as a causative factor in the development and progression of several forms of human cancer. As such, the development of small molecule inhibitors of Hh signaling as potential anti-cancer chemotherapeutics has been a major area of research interest in both academics and industry over the past ten years. Through these efforts, synthetic small molecules that target multiple components of the Hh pathway have been identified and advanced to preclinical or clinical development. The goal of this review is to provide an update on the current status of several synthetic small molecule Hh pathway inhibitors and explore the potential of several recently disclosed inhibitory scaffolds.
Export Options
About this article
Cite this article as:
Maschinot C.A., Pace J.R. and Hadden M.K., Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics, Current Medicinal Chemistry 2015; 22 (35) . https://dx.doi.org/10.2174/0929867322666150827093904
DOI https://dx.doi.org/10.2174/0929867322666150827093904 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance
Current Cancer Drug Targets Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Role of FoxP3<sup>+</sup> Treg Cells Mediating Immune Suppression in Leprosy
Current Immunology Reviews (Discontinued) The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry Erlotinib Hydrochloride Novel Drug Delivery Systems: A Mini Review Unravelling the Role of Micro- and Nanocarriers
Drug Delivery Letters Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design NS5A - From Obscurity to New Target for HCV Therapy
Recent Patents on Anti-Infective Drug Discovery Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry